
Global Influenza Drugs and Vaccines Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Influenza Drugs and Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Influenza Drugs and Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Influenza Drugs and Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Influenza Drugs and Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Influenza Drugs and Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Influenza Drugs and Vaccines market include CSL, Alvogen, AstraZeneca, BioCryst Pharmaceuticals, Bristol Myers Squibb, Celgene, Emergent Biosolutions, GlaxoSmithKline and Hulan Bio, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Influenza Drugs and Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Influenza Drugs and Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Influenza Drugs and Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Influenza Drugs and Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Influenza Drugs and Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Influenza Drugs and Vaccines sales, projected growth trends, production technology, application and end-user industry.
Influenza Drugs and Vaccines Segment by Company
CSL
Alvogen
AstraZeneca
BioCryst Pharmaceuticals
Bristol Myers Squibb
Celgene
Emergent Biosolutions
GlaxoSmithKline
Hulan Bio
Protein Sciences Corporation
Seqirus
Serum Institute of India
Viatris
Beike Bio
Bayer
Pfizer
Jiangsu GDK
Sinovac
Eli Lilly
Roche
Novartis
Sanofi
Changchun Institute of Biological
Influenza Drugs and Vaccines Segment by Type
Influenza Drugs
Influenza Vaccines
Influenza Drugs and Vaccines Segment by Application
Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Influenza Drugs and Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Influenza Drugs and Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Influenza Drugs and Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Influenza Drugs and Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Influenza Drugs and Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Drugs and Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza Drugs and Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Drugs and Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Influenza Drugs and Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenza Drugs and Vaccines industry.
Chapter 3: Detailed analysis of Influenza Drugs and Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Influenza Drugs and Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Influenza Drugs and Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Influenza Drugs and Vaccines market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Influenza Drugs and Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Influenza Drugs and Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Influenza Drugs and Vaccines market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Influenza Drugs and Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Influenza Drugs and Vaccines market include CSL, Alvogen, AstraZeneca, BioCryst Pharmaceuticals, Bristol Myers Squibb, Celgene, Emergent Biosolutions, GlaxoSmithKline and Hulan Bio, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Influenza Drugs and Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Influenza Drugs and Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Influenza Drugs and Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Influenza Drugs and Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Influenza Drugs and Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Influenza Drugs and Vaccines sales, projected growth trends, production technology, application and end-user industry.
Influenza Drugs and Vaccines Segment by Company
CSL
Alvogen
AstraZeneca
BioCryst Pharmaceuticals
Bristol Myers Squibb
Celgene
Emergent Biosolutions
GlaxoSmithKline
Hulan Bio
Protein Sciences Corporation
Seqirus
Serum Institute of India
Viatris
Beike Bio
Bayer
Pfizer
Jiangsu GDK
Sinovac
Eli Lilly
Roche
Novartis
Sanofi
Changchun Institute of Biological
Influenza Drugs and Vaccines Segment by Type
Influenza Drugs
Influenza Vaccines
Influenza Drugs and Vaccines Segment by Application
Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Influenza Drugs and Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Influenza Drugs and Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Influenza Drugs and Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Influenza Drugs and Vaccines significant trends, drivers, influence factors in global and regions.
6. To analyze Influenza Drugs and Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Drugs and Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza Drugs and Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Drugs and Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Influenza Drugs and Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenza Drugs and Vaccines industry.
Chapter 3: Detailed analysis of Influenza Drugs and Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Influenza Drugs and Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Influenza Drugs and Vaccines in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
218 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Influenza Drugs and Vaccines Sales Value (2020-2031)
- 1.2.2 Global Influenza Drugs and Vaccines Sales Volume (2020-2031)
- 1.2.3 Global Influenza Drugs and Vaccines Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Influenza Drugs and Vaccines Market Dynamics
- 2.1 Influenza Drugs and Vaccines Industry Trends
- 2.2 Influenza Drugs and Vaccines Industry Drivers
- 2.3 Influenza Drugs and Vaccines Industry Opportunities and Challenges
- 2.4 Influenza Drugs and Vaccines Industry Restraints
- 3 Influenza Drugs and Vaccines Market by Company
- 3.1 Global Influenza Drugs and Vaccines Company Revenue Ranking in 2024
- 3.2 Global Influenza Drugs and Vaccines Revenue by Company (2020-2025)
- 3.3 Global Influenza Drugs and Vaccines Sales Volume by Company (2020-2025)
- 3.4 Global Influenza Drugs and Vaccines Average Price by Company (2020-2025)
- 3.5 Global Influenza Drugs and Vaccines Company Ranking (2023-2025)
- 3.6 Global Influenza Drugs and Vaccines Company Manufacturing Base and Headquarters
- 3.7 Global Influenza Drugs and Vaccines Company Product Type and Application
- 3.8 Global Influenza Drugs and Vaccines Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Influenza Drugs and Vaccines Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Influenza Drugs and Vaccines Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Influenza Drugs and Vaccines Market by Type
- 4.1 Influenza Drugs and Vaccines Type Introduction
- 4.1.1 Influenza Drugs
- 4.1.2 Influenza Vaccines
- 4.2 Global Influenza Drugs and Vaccines Sales Volume by Type
- 4.2.1 Global Influenza Drugs and Vaccines Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Influenza Drugs and Vaccines Sales Volume by Type (2020-2031)
- 4.2.3 Global Influenza Drugs and Vaccines Sales Volume Share by Type (2020-2031)
- 4.3 Global Influenza Drugs and Vaccines Sales Value by Type
- 4.3.1 Global Influenza Drugs and Vaccines Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Influenza Drugs and Vaccines Sales Value by Type (2020-2031)
- 4.3.3 Global Influenza Drugs and Vaccines Sales Value Share by Type (2020-2031)
- 5 Influenza Drugs and Vaccines Market by Application
- 5.1 Influenza Drugs and Vaccines Application Introduction
- 5.1.1 Retail Pharmacy
- 5.1.2 Online Pharmacy
- 5.1.3 Hospital Pharmacy
- 5.2 Global Influenza Drugs and Vaccines Sales Volume by Application
- 5.2.1 Global Influenza Drugs and Vaccines Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Influenza Drugs and Vaccines Sales Volume by Application (2020-2031)
- 5.2.3 Global Influenza Drugs and Vaccines Sales Volume Share by Application (2020-2031)
- 5.3 Global Influenza Drugs and Vaccines Sales Value by Application
- 5.3.1 Global Influenza Drugs and Vaccines Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Influenza Drugs and Vaccines Sales Value by Application (2020-2031)
- 5.3.3 Global Influenza Drugs and Vaccines Sales Value Share by Application (2020-2031)
- 6 Influenza Drugs and Vaccines Regional Sales and Value Analysis
- 6.1 Global Influenza Drugs and Vaccines Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Influenza Drugs and Vaccines Sales by Region (2020-2031)
- 6.2.1 Global Influenza Drugs and Vaccines Sales by Region: 2020-2025
- 6.2.2 Global Influenza Drugs and Vaccines Sales by Region (2026-2031)
- 6.3 Global Influenza Drugs and Vaccines Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Influenza Drugs and Vaccines Sales Value by Region (2020-2031)
- 6.4.1 Global Influenza Drugs and Vaccines Sales Value by Region: 2020-2025
- 6.4.2 Global Influenza Drugs and Vaccines Sales Value by Region (2026-2031)
- 6.5 Global Influenza Drugs and Vaccines Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Influenza Drugs and Vaccines Sales Value (2020-2031)
- 6.6.2 North America Influenza Drugs and Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Influenza Drugs and Vaccines Sales Value (2020-2031)
- 6.7.2 Europe Influenza Drugs and Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Influenza Drugs and Vaccines Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Influenza Drugs and Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Influenza Drugs and Vaccines Sales Value (2020-2031)
- 6.9.2 South America Influenza Drugs and Vaccines Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Influenza Drugs and Vaccines Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Influenza Drugs and Vaccines Sales Value Share by Country, 2024 VS 2031
- 7 Influenza Drugs and Vaccines Country-level Sales and Value Analysis
- 7.1 Global Influenza Drugs and Vaccines Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Influenza Drugs and Vaccines Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Influenza Drugs and Vaccines Sales by Country (2020-2031)
- 7.3.1 Global Influenza Drugs and Vaccines Sales by Country (2020-2025)
- 7.3.2 Global Influenza Drugs and Vaccines Sales by Country (2026-2031)
- 7.4 Global Influenza Drugs and Vaccines Sales Value by Country (2020-2031)
- 7.4.1 Global Influenza Drugs and Vaccines Sales Value by Country (2020-2025)
- 7.4.2 Global Influenza Drugs and Vaccines Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.9.2 France Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.16.2 China Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.19.2 India Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Influenza Drugs and Vaccines Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Influenza Drugs and Vaccines Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Influenza Drugs and Vaccines Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 CSL
- 8.1.1 CSL Comapny Information
- 8.1.2 CSL Business Overview
- 8.1.3 CSL Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.1.4 CSL Influenza Drugs and Vaccines Product Portfolio
- 8.1.5 CSL Recent Developments
- 8.2 Alvogen
- 8.2.1 Alvogen Comapny Information
- 8.2.2 Alvogen Business Overview
- 8.2.3 Alvogen Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Alvogen Influenza Drugs and Vaccines Product Portfolio
- 8.2.5 Alvogen Recent Developments
- 8.3 AstraZeneca
- 8.3.1 AstraZeneca Comapny Information
- 8.3.2 AstraZeneca Business Overview
- 8.3.3 AstraZeneca Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.3.4 AstraZeneca Influenza Drugs and Vaccines Product Portfolio
- 8.3.5 AstraZeneca Recent Developments
- 8.4 BioCryst Pharmaceuticals
- 8.4.1 BioCryst Pharmaceuticals Comapny Information
- 8.4.2 BioCryst Pharmaceuticals Business Overview
- 8.4.3 BioCryst Pharmaceuticals Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.4.4 BioCryst Pharmaceuticals Influenza Drugs and Vaccines Product Portfolio
- 8.4.5 BioCryst Pharmaceuticals Recent Developments
- 8.5 Bristol Myers Squibb
- 8.5.1 Bristol Myers Squibb Comapny Information
- 8.5.2 Bristol Myers Squibb Business Overview
- 8.5.3 Bristol Myers Squibb Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Bristol Myers Squibb Influenza Drugs and Vaccines Product Portfolio
- 8.5.5 Bristol Myers Squibb Recent Developments
- 8.6 Celgene
- 8.6.1 Celgene Comapny Information
- 8.6.2 Celgene Business Overview
- 8.6.3 Celgene Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Celgene Influenza Drugs and Vaccines Product Portfolio
- 8.6.5 Celgene Recent Developments
- 8.7 Emergent Biosolutions
- 8.7.1 Emergent Biosolutions Comapny Information
- 8.7.2 Emergent Biosolutions Business Overview
- 8.7.3 Emergent Biosolutions Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Emergent Biosolutions Influenza Drugs and Vaccines Product Portfolio
- 8.7.5 Emergent Biosolutions Recent Developments
- 8.8 GlaxoSmithKline
- 8.8.1 GlaxoSmithKline Comapny Information
- 8.8.2 GlaxoSmithKline Business Overview
- 8.8.3 GlaxoSmithKline Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.8.4 GlaxoSmithKline Influenza Drugs and Vaccines Product Portfolio
- 8.8.5 GlaxoSmithKline Recent Developments
- 8.9 Hulan Bio
- 8.9.1 Hulan Bio Comapny Information
- 8.9.2 Hulan Bio Business Overview
- 8.9.3 Hulan Bio Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Hulan Bio Influenza Drugs and Vaccines Product Portfolio
- 8.9.5 Hulan Bio Recent Developments
- 8.10 Protein Sciences Corporation
- 8.10.1 Protein Sciences Corporation Comapny Information
- 8.10.2 Protein Sciences Corporation Business Overview
- 8.10.3 Protein Sciences Corporation Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Protein Sciences Corporation Influenza Drugs and Vaccines Product Portfolio
- 8.10.5 Protein Sciences Corporation Recent Developments
- 8.11 Seqirus
- 8.11.1 Seqirus Comapny Information
- 8.11.2 Seqirus Business Overview
- 8.11.3 Seqirus Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Seqirus Influenza Drugs and Vaccines Product Portfolio
- 8.11.5 Seqirus Recent Developments
- 8.12 Serum Institute of India
- 8.12.1 Serum Institute of India Comapny Information
- 8.12.2 Serum Institute of India Business Overview
- 8.12.3 Serum Institute of India Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Serum Institute of India Influenza Drugs and Vaccines Product Portfolio
- 8.12.5 Serum Institute of India Recent Developments
- 8.13 Viatris
- 8.13.1 Viatris Comapny Information
- 8.13.2 Viatris Business Overview
- 8.13.3 Viatris Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Viatris Influenza Drugs and Vaccines Product Portfolio
- 8.13.5 Viatris Recent Developments
- 8.14 Beike Bio
- 8.14.1 Beike Bio Comapny Information
- 8.14.2 Beike Bio Business Overview
- 8.14.3 Beike Bio Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Beike Bio Influenza Drugs and Vaccines Product Portfolio
- 8.14.5 Beike Bio Recent Developments
- 8.15 Bayer
- 8.15.1 Bayer Comapny Information
- 8.15.2 Bayer Business Overview
- 8.15.3 Bayer Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Bayer Influenza Drugs and Vaccines Product Portfolio
- 8.15.5 Bayer Recent Developments
- 8.16 Pfizer
- 8.16.1 Pfizer Comapny Information
- 8.16.2 Pfizer Business Overview
- 8.16.3 Pfizer Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Pfizer Influenza Drugs and Vaccines Product Portfolio
- 8.16.5 Pfizer Recent Developments
- 8.17 Jiangsu GDK
- 8.17.1 Jiangsu GDK Comapny Information
- 8.17.2 Jiangsu GDK Business Overview
- 8.17.3 Jiangsu GDK Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.17.4 Jiangsu GDK Influenza Drugs and Vaccines Product Portfolio
- 8.17.5 Jiangsu GDK Recent Developments
- 8.18 Sinovac
- 8.18.1 Sinovac Comapny Information
- 8.18.2 Sinovac Business Overview
- 8.18.3 Sinovac Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.18.4 Sinovac Influenza Drugs and Vaccines Product Portfolio
- 8.18.5 Sinovac Recent Developments
- 8.19 Eli Lilly
- 8.19.1 Eli Lilly Comapny Information
- 8.19.2 Eli Lilly Business Overview
- 8.19.3 Eli Lilly Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.19.4 Eli Lilly Influenza Drugs and Vaccines Product Portfolio
- 8.19.5 Eli Lilly Recent Developments
- 8.20 Roche
- 8.20.1 Roche Comapny Information
- 8.20.2 Roche Business Overview
- 8.20.3 Roche Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.20.4 Roche Influenza Drugs and Vaccines Product Portfolio
- 8.20.5 Roche Recent Developments
- 8.21 Novartis
- 8.21.1 Novartis Comapny Information
- 8.21.2 Novartis Business Overview
- 8.21.3 Novartis Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.21.4 Novartis Influenza Drugs and Vaccines Product Portfolio
- 8.21.5 Novartis Recent Developments
- 8.22 Sanofi
- 8.22.1 Sanofi Comapny Information
- 8.22.2 Sanofi Business Overview
- 8.22.3 Sanofi Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.22.4 Sanofi Influenza Drugs and Vaccines Product Portfolio
- 8.22.5 Sanofi Recent Developments
- 8.23 Changchun Institute of Biological
- 8.23.1 Changchun Institute of Biological Comapny Information
- 8.23.2 Changchun Institute of Biological Business Overview
- 8.23.3 Changchun Institute of Biological Influenza Drugs and Vaccines Sales, Value and Gross Margin (2020-2025)
- 8.23.4 Changchun Institute of Biological Influenza Drugs and Vaccines Product Portfolio
- 8.23.5 Changchun Institute of Biological Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Influenza Drugs and Vaccines Value Chain Analysis
- 9.1.1 Influenza Drugs and Vaccines Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Influenza Drugs and Vaccines Sales Mode & Process
- 9.2 Influenza Drugs and Vaccines Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Influenza Drugs and Vaccines Distributors
- 9.2.3 Influenza Drugs and Vaccines Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.